A clinical trial was conducted to compare intramuscular (im) with subcutaneous (sc) routes for administration of quadrivalent meningococcal polysaccharide vaccine in 141 adults. Safety assessment showed the im route had reduced erythema ( ) and reduced headache on days 1 and 2 ( ). P ! .01 P ! .05 Serological testing for serum bactericidal antibody titers against capsular groups A and C did not detect significant differences.
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Until recently, meningococcal polysaccharide vaccines have been used in limited circumstances. These circumstances include the following: for management and control of disease outbreaks; for persons traveling to areas, such as the "meningitis belt" of Africa, where the disease is endemic; for persons with selected immunodeficiency, such as complement deficiency; for persons who have asplenia; and finally, for prevention of outbreaks among military recruits [1] . At present, there is heightened recognition that college students who reside in dormitories have an increased risk for meningococcal disease, compared with college students overall and with the general adult population [2, 3] . The Centers for Disease Control (Atlanta) recently issued new recommendations for informing college students of the severity of meningococcal disease and of the availability of a vaccine to prevent this disease [4] . As a result, more frequent use of the currently available polysaccharide vaccine Menomune can be expected.
The quadrivalent meningococcal polysaccharide vaccine currently is licensed for sc administration [5] . The present study was undertaken to compare the safety and serological profile of the vaccine given by the sc route with the vaccine given by the im route.
Other trials of vaccines have compared im administration with sc administration to determine differences in immunogenicity and side effects. In a trial of subunit influenza vaccine, im administration resulted in fewer side effects than did vaccine given by the sc route, and immunogenicity was similar for both routes [6] . Another study of children's strength diphtheria and tetanus (DT) vaccine showed significant reduction of local reactions with vaccine given by the im route, with no differences in antibody response [7] . Invariably, vaccine given by the im route has been superior to that given by the sc route for reactogenicity, although immunogenicity of the vaccine is similar for both routes of administration.
The present study reports on a randomized trial with 2 study groups (sc and im). A data coordinator from Aventis Pasteur generated a randomization list. Subjects were randomized into blocks of 8 to achieve equal distribution of the groups. Eligible, healthy adult volunteers received, after providing written informed consent, a single 0.5-mL sc or im injection of meningococcal polysaccharide vaccine that contained capsular groups A, C, Y, and W-135 combined (Menomune, Aventis Pasteur). The sc injections of vaccine into the posterior arm were done using a 25-gauge, 5/8" needle, and im injections of vaccine into the lateral deltoid muscle were done using a needle of the same size. Blood samples for serological testing were collected prior to immunization and at 28-30 days after immunization. To evaluate safety and to assess local and systemic reactions, clinic visits were made at 1, 2, and 28-30 days after immunization. Safety evaluation, which was done by one individual, was not done in a blinded manner because of the different sites for injection. The local reaction of tenderness was assessed by touching the site of injection, whereas pain/soreness was assessed by requesting that the subject move the arm into which the vaccine was injected; any symptoms resulting from this motion were reported. Erythema and swelling were measured using a ruler. Temperature was recorded, whereas symptoms of chills, headache, dizziness and malaise were determined by patients' positive or negative responses to questions about the presence of such symptoms.
The results of safety parameters were assessed using a 2-sided a In group A, 59 of 67 subjects had a 4-fold increase in antibody titers; in group C, 55 of 67 subjects had a 4-fold increase in antibody titers. b In group A, 61 of 66 subjects had a 4-fold increase in antibody titers; in group C, 55 of 66 subjects had a 4-fold increase in antibody titers.
x 2 test. For immunogenicity results, geometric means were compared with use of the analysis of variance (ANOVA) F test, and seroconversions (4-fold increases) were compared using a 2-sided x 2 test. A total of 141 healthy adults (approximately equal numbers of men and women) were enrolled in the study. The mean age at entry was 21.9 years for those randomized to receive the im injection and 20.6 years for those randomized to receive the sc injection. The majority of study participants were white, and there were no statistically significant differences between vaccine groups with regard to age at entry, sex, or ethnic origin. A total of 133 subjects completed the study per protocol (7 were lost to follow-up, and treatment was discontinued for 1 when it was discovered that the subject had previously received Menomune). Of those who completed the study per protocol, 67 received vaccine by the im route and 66 by the sc route.
Safety assessment is shown in Table 1 . For local reactions, results show that erythema measuring !1 inch in diameter occurred more frequently in subjects receiving vaccine by the sc route compared with im (11.4% vs. 31.9%, ). Ery-P ! .01 thema 11 inch in diameter and swelling did not differ significantly between study groups. Tenderness and pain/soreness also were not significantly different between study groups.
Systemic reactions were infrequent in both groups; however, headache on both day 1 and day 2 was more frequent (P ! ) in the sc group. No significant differences were detected .05 for prevalence of fever (1 patient overall), chills (3), dizziness (1), malaise (6), myalgia (2), nausea (2 patients on day 1 and 3 on day 2), vomiting (1), and diarrhea (1). One or more systemic reactions were experienced by 8 subjects in the im group and by 17 patients in the sc group.
Serological responses were assessed using a serum bactericidal assay [8] for meningococcal capsular groups A and C. These groups were selected as being representative of overall responses. No significant differences were detected between the study groups for immunogenicity of the vaccine. The results of geometric mean, range, and interquartile titers to the capsular groups both prevaccine and postvaccine are shown in table 2, as are % 4-fold increases in antibody titers to the capsular groups. Every subject given vaccine by the im route had postvaccine antibody titers to groups A and C that were у8, whereas 1 of 66 persons given vaccine by the sc route failed to demonstrate such a postvaccine titer. Although "assignment of a level of total antimeningococcal antibody that is protective against clinical disease is problematic" [9] , a total anticapsular antibody level of у2 mg has been considered protective against invasive meningococcal disease [10] .
We conclude from these results that Menomune, whether given im or sc, elicits similar safety and immunogenicity profiles. However, using the im route can reduce both the occurrence of redness at the injection site and the occurrence of headaches postvaccine.
